Independent Group Finds Multiple Myeloma Drugs Too Costly in US

U.S. prices for newer multiple myeloma cancer treatments should be cut by as much as 94 percent to justify their value in terms of prolonging life, while there is not enough evidence to assess the benefit of some, according to an independent nonprofit organization that evaluates the effectiveness of medicines. 


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.